
PEDIATRIC (<18 YEARS OF AGE) GROWTH HORMONE PRIOR AUTHORIZATION REQUEST FORM



Today's D	ate			
/		/		

Note: This form must be completed by the prescribing provider.

All sections must be completed or the request will be returned

Patient's Medicaid #	Date of Birth
Patient's Name	Prescriber's Name
Prescriber's IN License #	Specialty
Prescriber's NPI #	Prescriber's Signature
Return Fax #	Return Phone #
Check box if requesting retro-active PA	Date(s) of service requested for retro-active eligibility (if applicable):

Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility timelines) with dates of service prior to 30 calendar days of submission separately from current PA requests (dates of service 30 calendar days or less and going forward).

Requested Medication and Strength	Dosage	Treatment Duration

SOMATROPIN AGENTS – Initial Authorization		
Please select the member's diagnosis:		
Growth hormone deficiency		
Noonan syndrome (Norditropin only)		
Prader-Willi syndrome		
Renal function impairment associated with growth failure (Nutropin AQ only)		
□ Short-stature homeobox-containing gene (SHOX) deficiency (Humatrope or Zomacton only)		
□ Small for gestational age (SGA)		
Turner syndrome		
Other* (please provide diagnosis)		
Diagnosis of Idiopathic short stature Yes No N/A		
The following documentation will be required for the above diagnosis		
Confirmatory growth chart documentation is required illustrating both of the following:		
 Height measurement of more than 2.0 standard deviations below population mean for given 		
age		
 Growth rate of 5 cm/year or less prior to starting growth hormone therapy 		

Please complete the following:
Current height: (inches)
Height 6 months prior:(inches)
Height 12 months prior:(inches)
Diagnosis of HIV-associated wasting or cachexia (Serostim only) 🗌 Yes 🔲 No 🗌 N/A
 *The following documentation will be required for the above diagnosis Quantitative measurement of lean body mass using DEXA (dual energy X-ray absorptiometry) or BIA (bioelectric impedance analysis) Documentation of involuntary weight loss of >10% of baseline total body weight OR body cell mass <30% for initial approval
Member's current AIDS/HIV anti-retroviral regimen:
Member has tried and failed the one other therapy for HIV-associated wasting or cachexia [e.g., anabolic steroids (include medication name, trial date, dose, frequency, duration, reason for failure)]
 The following documentation will be required for any of the above diagnoses (except for HIV-associated wasting or cachexia indication being treated by Serostim): Documentation of biochemical evidence or other applicable testing supporting the diagnosis is required Radiology report documenting a bone age of 14-15 or less in members assigned female at birth, 16-17 or less in members assigned male at birth Radiology report documenting open epiphyses (NOTE: documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age)
Please select one of the following for ALL indications:
Request is for a non-preferred agent with a product-specific indication:
List indication: Prescriber would like to utilize a non-preferred agent over preferred agent based on the following medical justification:
For ALL indications – Prescriber attests that they have performed all necessary testing to ensure there are no expanding intracranial lesions or tumors prior to initiating growth hormone therapy
I,hereby attest that I have performed all necessary testing
I,hereby attest that I have performed all necessary testing to ensure that this member does not have expanding intracranial lesions or tumors prior to initiating growth hormone therapy.
Prescriber Signature:

SOMATROPIN AGENTS – Re	authorization				
Please select one of the following:					
Member has a diagnosis from		other than HIV-assoc	iated wasting or cac	chexia	
Please select one of the	-				
Request is for a preferred agent					
	Request is for a non-preferred agent with a product-specific indication:				
	List indication:				
Prescriber would	\Box Prescriber would like to utilize a non-preferred agent over preferred agent based on the				
following medica	l justification:				
					
The following documer or cachexia:	tation will be requir	ed for diagnoses otl	her than HIV-assoc	ciated wasting	
	ocumenting a bone age or bers assigned male	-	members assigned	female at birth,	
	ocumenting open epi		mented evidence of	open epiphyses	
	ember is nearing or a	• •			
The following documerGrowth rate of 2 to	tation will be requir 2.5 cm/year or more	-	-		
If no , please provide	-	-			
	-				
*For ALL indications other t continuing to monitor the men malignant transformation of sł Ses Doo	nber for intracranial tu	mor recurrence, prog		•	
I, member for intracranial tum transformation of skin lesio			at I am continuing Ig disease, or mali		
Prescriber Signature:					
 Member has a diagnosis of therapy 				h hormone	
Member's current All	DS/HIV anti-retroviral	regimen:		·····	
 Member has demonstrated baseline (document 	strated an increase in ation required)	total body weight or l	ean body mass fron	n treatment	
The following documer cachexia:	tation will be requir	ed for a diagnosis o	f HIV-associated w	asting or	
Current:	height:	(inches)	weight:	(lbs)	
3 months prior:	height:	(inches)	weight:	(lbs)	
6 months prior:	height:	(inches)	weight:	(lbs)	

INCRELEX (MECASERMIN) – Initial Authorization			
Diagnosis of growth failure due to severe primary insulin-like growth factor-1 deficiency (primary IGFD) OR growth hormone (GH) gene deletion with acquired neutralizing antibodies to GH \Box Yes \Box No			
Member is greater than or equal to 2 years of age and less than 18 years of age \Box Yes $\ \Box$ No			
The following documentation will be required for the above diagnosis			
Radiology report documenting open epiphyses			
Documentation of baseline height and weight			
Please complete the following:			
 Baseline height: (inches) 			
 Baseline weight:(kg or lb) 			
INCRELEX (MECASERMIN) – Reauthorization			
Member is less than 18 years of age 🗌 Yes 🔲 No			
Improvement in annualized growth velocity (AGV) OR provider has submitted valid medical justification for continued use \Box Yes \Box No			
Please complete the following:			
 Current height: (inches) 			
 Height 6 months prior:(inches) 			
 Height 12 months prior:(inches) 			
 The following documentation will be required for the above diagnosis Radiology report documenting open epiphyses 			
NGENLA (SOMATROGON-GHLA) – Initial Authorization			
Diagnosis of growth failure due to growth hormone deficiency $\ \square$ Yes $\ \square$ No			
Member is 3 years of age or older and less than 18 years of age $\ \square$ Yes $\ \square$ No			
The following documentation will be required for the above diagnosis			
Documentation of biochemical evidence or other applicable testing supporting the diagnosis is required			
Radiology report documenting a bone age of 14-15 or less in females, 16-17 or less in males			
 Radiology report documenting open epiphyses (<u>NOTE:</u> documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age)) 			
Previous trial and failure of Skytrofa (lonapegsomatropin) 🛛 Yes 🗌 No			
If yes, please provide chart documentation or dates of use			
If no, please provide medical justification as to why Skytrofa (lonapegsomatropin) is unsuitable for use:			

Provider attests that they have performed all necessary testing to ensure there are no expanding intracranial lesions or tumors prior to initiating growth hormone therapy \Box Yes \Box No
I,hereby attest that I have performed all necessary testing to ensure that this member does not have expanding intracranial lesions or tumors that could be negatively impacted by growth hormone therapy.
Prescriber Signature:
NGENLA (SOMATROGON-GHLA) – Reauthorization
The following documentation will be required for any of the indicated diagnoses
 Radiology report documenting a bone age of 14-15 or less in females, 16-17 or less in males Radiology report documenting open epiphyses (<u>NOTE:</u> documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age))
Member is less than 18 years of age \Box Yes \Box No
Provider attests that they are continuing to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate \Box Yes \Box No
I,hereby attest that I continue to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate.
Prescriber Signature:
SKYTROFA (LONAPEGSOMATROPIN-TCGD) – Initial Authorization
SKYTROFA (LONAPEGSOMATROPIN-TCGD) – Initial Authorization Diagnosis of growth failure due to growth hormone deficiency Yes No
Diagnosis of growth failure due to growth hormone deficiency ☐ Yes ☐ No Member is less than 18 years of age AND weighs 11.5 kg or greater ☐ Yes ☐ No ○ Weight: (kg or lb)
Diagnosis of growth failure due to growth hormone deficiency □ Yes □ No Member is less than 18 years of age AND weighs 11.5 kg or greater □ Yes □ No
 Diagnosis of growth failure due to growth hormone deficiency ☐ Yes ☐ No Member is less than 18 years of age AND weighs 11.5 kg or greater ☐ Yes ☐ No Weight:
 Diagnosis of growth failure due to growth hormone deficiency ☐ Yes ☐ No Member is less than 18 years of age AND weighs 11.5 kg or greater ☐ Yes ☐ No Weight:
 Diagnosis of growth failure due to growth hormone deficiency ☐ Yes ☐ No Member is less than 18 years of age AND weighs 11.5 kg or greater ☐ Yes ☐ No Weight:
 Diagnosis of growth failure due to growth hormone deficiency ☐ Yes ☐ No Member is less than 18 years of age AND weighs 11.5 kg or greater ☐ Yes ☐ No Weight:

I, _____hereby attest that I have performed all necessary testing to ensure that this member does not have expanding intracranial lesions or tumors that could be negatively impacted by growth hormone therapy.

Prescriber Signature: _____

SKYTROFA (LONAPEGSOMATROPIN-TCGD) – Reauthorization
 The following documentation will be required for any of the indicated diagnoses Radiology report documenting a bone age of 14-15 or less in females, 16-17 or less in males Radiology report documenting open epiphyses (<u>NOTE:</u> documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age))
Member is less than 18 years of age \Box Yes \Box No
Provider attests that they are continuing to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate \Box Yes \Box No
I,hereby attest that I continue to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate. Prescriber Signature:
SOGROYA (SOMAPACITAN) – Initial Authorization
Diagnosis of growth failure due to growth hormone deficiency
Member is 2.5 years of age or older and less than 18 years of age $\ \square$ Yes $\ \square$ No
 The following documentation will be required for the above diagnosis Documentation of biochemical evidence or other applicable testing supporting the diagnosis is required Radiology report documenting a bone age of 14-15 or less in females, 16-17 or less in males Radiology report documenting open epiphyses (<u>NOTE:</u> documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age)) Previous trial and failure of Skytrofa (lonapegsomatropin) □ Yes □ No If yes, please provide chart documentation or dates of use If no, please provide medical justification as to why Skytrofa (lonapegsomatropin) is unsuitable for use:
Provider attests that they have performed all necessary testing to ensure there are no expanding intracranial lesions or tumors prior to initiating growth hormone therapy
I,hereby attest that I have performed all necessary testing
to ensure that this member does not have expanding intracranial lesions or tumors that could be negatively impacted by growth hormone therapy.
Prescriber Signature:

SOGROYA (SOMAPACITAN) – Reauthorization				
 The following documentation will be required for any of the indicated diagnoses Radiology report documenting a bone age of 14-15 or less in females, 16-17 or less in males Radiology report documenting open epiphyses (<u>NOTE:</u> documented evidence of open epiphyses is needed only if member is nearing or at puberty (estimate age range 10-17 years of age)) 				
Member is less than 18 years of age \Box Yes \Box No				
Provider attests that they are continuing to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate \Box Yes \Box No				
I,hereby attest that I continue to monitor the member for intracranial tumor recurrence, progression of underlying disease, or malignant transformation of skin lesions, if appropriate.				
Prescriber Signature:				
VOXZOGO (VOSORITIDE) – Initial Authorization				
Diagnosis of achondroplasia 🗌 Yes 🗌 No				
Member is less than 18 years of age \Box Yes \Box No				
 The following documentation will be required for the above diagnosis Radiology report documenting open epiphyses Documentation of baseline height and weight 				
Please complete the following:				
 Baseline height: (inches) 				
 Baseline weight:(kg or lb) 				
VOXZOGO (VOSORITIDE) – Reauthorization				
Member is less than 18 years of age 🗌 Yes 🗌 No				
Improvement in annualized growth velocity (AGV) of 1.5 cm/year OR provider has submitted valid medical justification for continued use				
Please complete the following:				
 Current height: (inches) 				
 Height 6 months prior:(inches) 				
 Height 12 months prior:(inches) 				
 The following documentation will be required for the above diagnosis Radiology report documenting open epiphyses 				

Radiology report documenting open epiphyses

CONFIDENTIAL INFORMATION

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.